Addex Therapeutics is a clinical-stage pharmaceutical company specializing in the development and commercialization of a groundbreaking class of orally available small molecule drugs called allosteric modulators. With a focus on neurological disorders, Addex Therapeutics aims to revolutionize the field of medicine through its innovative products. Their pipeline boasts a range of clinical and pre-clinical drugs, targeting various conditions such as epilepsy, PD-LID, substance use disorder, chronic cough, schizophrenia, Parkinson's disease, and neurodegenerative disorders.

By employing their unique technology platform of allosteric modulation, Addex Therapeutics strives to provide effective and transformative treatments for patients. In addition to their research and development efforts, Addex Therapeutics actively engages in partnerships and collaborations within the industry, driving innovation and expanding their capabilities. They have made significant strides in their field, as demonstrated by positive results from their studies.

Stay up-to-date with the latest news and developments from Addex Therapeutics, and join their mission to redefine healthcare. Contact Addex Therapeutics for more information and to learn about potential opportunities in this exciting and vital industry